![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
January 25, 2021
This phase I/II study, led by Dr. Jonathon Cohen, is evaluating the combination of ibrutinib and the oral proteasome inhibitor ixazomib in patients with relapsed/refractory mantle cell lymphoma
January 25, 2021
December 14, 2020
Lessons learned from our first virtual Group Meeting and a new leadership appointment
December 14, 2020
The five phase III trials span different cancer types: prostate, leukemia, anal, lung, and myeloma
December 14, 2020
EA2174 will evaluate the role of perioperative immunotherapy for patients with esophageal or gastroesophageal junction adenocarcinoma
December 14, 2020
Already among the most influential thought leaders in cardio-oncology, Dr. Ky is the first in this field to receive the Group’s highest research distinction
December 14, 2020
October 23, 2020
The purpose of the Symposium is to introduce young investigators to ECOG-ACRIN and provide them with a forum to present their research in a formal manner and obtain feedback
October 20, 2020
What are the elements of a productive meeting when we get together – and what might they look like in a virtual format?
October 19, 2020
The Fall 2020 Group Meeting will look different this year – a fact that should not be too surprising, given that it will take place entirely online
October 19, 2020
The Journal of Clinical Oncology published new data from the NCI-MATCH precision medicine cancer trial that has broad relevance in medicine and provides a roadmap for future precision medicine trials
October 19, 2020
October accrual is on pace to be the highest month on record. Since July 1, TMIST has enrolled more patients than all other National Cancer Institute clinical trials combined. An unheard-of number (nearly 20%) are Black and African American women. Drs. Etta Pisano and Mitch Schnall provide the latest status of the trial and discuss its continuing relevance